Aiforia Technologies Oyj (AIFORIA) Stock Overview
Together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software in Finland, the rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AIFORIA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aiforia Technologies Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.22 |
| 52 Week High | €4.80 |
| 52 Week Low | €3.11 |
| Beta | 0.28 |
| 1 Month Change | 0% |
| 3 Month Change | -7.47% |
| 1 Year Change | -30.75% |
| 3 Year Change | -16.21% |
| 5 Year Change | n/a |
| Change since IPO | -36.36% |
Recent News & Updates
Shareholder Returns
| AIFORIA | FI Healthcare Services | FI Market | |
|---|---|---|---|
| 7D | -2.1% | 0.06% | -0.3% |
| 1Y | -30.8% | 29.5% | 7.9% |
Return vs Industry: AIFORIA underperformed the Finnish Healthcare Services industry which returned 30.7% over the past year.
Return vs Market: AIFORIA underperformed the Finnish Market which returned 7.8% over the past year.
Price Volatility
| AIFORIA volatility | |
|---|---|
| AIFORIA Average Weekly Movement | 4.6% |
| Healthcare Services Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FI Market | 7.5% |
| 10% least volatile stocks in FI Market | 2.6% |
Stable Share Price: AIFORIA has not had significant price volatility in the past 3 months compared to the Finnish market.
Volatility Over Time: AIFORIA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 77 | Jukka Tapaninen | www.aiforia.com |
Aiforia Technologies Oyj, together with its subsidiary Aiforia Inc., equips pathologists and scientists in preclinical, clinical, and academic labs with deep learning artificial intelligence (AI) software in Finland, the rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer; CE-IVD marked Aiforia clinical suite viewer for the clinical pathology workflow; and Aiforia Create, an agile solution to develop an AI model for image analysis application. The company’s products are used for the treatment of Parkinson’s disease, organ transplantation, and liver and inflammatory bowel diseases.
Aiforia Technologies Oyj Fundamentals Summary
| AIFORIA fundamental statistics | |
|---|---|
| Market cap | €101.77m |
| Earnings (TTM) | -€11.95m |
| Revenue (TTM) | €2.85m |
Is AIFORIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIFORIA income statement (TTM) | |
|---|---|
| Revenue | €2.85m |
| Cost of Revenue | €7.54m |
| Gross Profit | -€4.68m |
| Other Expenses | €7.26m |
| Earnings | -€11.95m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 28, 2025
| Earnings per share (EPS) | -0.38 |
| Gross Margin | -164.24% |
| Net Profit Margin | -418.90% |
| Debt/Equity Ratio | 35.6% |
How did AIFORIA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/22 07:45 |
| End of Day Share Price | 2025/07/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aiforia Technologies Oyj is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antti Luiro | Inderes Oy |
| Frans-Mikael Rostedt | Inderes Oy |
| Roni Peuranheimo | Inderes Oy |